National
PROJECT TITLE: Addressing Complexity of LeukemiA genome by chRomatIn 3D sTructure analYsis: translational opportunities
Principal Investigator: Prof. Alessandro Maria Vannucchi
Funding Agency: AIRC - Investigator Grant 2025
Funding Amount: €967,000
PROJECT TITLE: Serine metabolism heterogeneity in chemoresistance of colorectal cancer to 5-Fluorouracil
Principal Investigator: Prof. Maria Letizia Taddei
Funding Agency: AIRC - Investigator Grant 2022
Funding Amount: €432,000
PROJECT TITLE: Senectus ipsa morbus est?- How to distinguish inflammaging from clonal myelodysplastic syndromes
Principal Investigator: Prof. Valeria Santini
Funding Agency: AIRC - Investigator Grant 2021
Funding Amount: €959,000
PROJECT TITLE: Interregional multidisciplinary hub for research and clinical trials to combat pandemics and antibiotic resistance
Principal Investigator: Prof. Gianmaria Rossolini
Funding Agency: Ministry of Health
Funding Amount: €160,000
PROJECT TITLE: Non-auditory effects of noise in school, university, and hospital environments and risk management of related accidents
Principal Investigator: Prof. Nicola Mucci
Funding Agency: INAIL (National Institute for Insurance against Workplace Accidents)
Funding Amount: €132,000
PROJECT TITLE: APL-like subset within NPM1-mutated acute myeloid leukemia: a distinct phenotypic signature correlating with early-onset vascular complications
Principal Investigator: Prof. Francesco Mannelli
Funding Agency: GIMEMA Foundation
Funding Amount: €66,000
PROJECT TITLE: Prevention and Treatment of Periodontal Diseases in Children with Behavioral Disabilities: An Integrated Model for Oral Health
Principal Investigator: Prof. Francesco Cairo
Funding Agency: Ministry of Health - CCM Programme (National Centre for Disease Prevention and Control)
Funding Amount: €92,000
PROJECT TITLE: Regenerative medicine strategies for future space exploration missions - SATURNO
Principal Investigator: Prof. Daniele Bani
Funding Agency: Italian Space Agency
Funding Amount: €31,600
PROJECT TITLE: Viral Infection and Bystander immune Responses to explain AutoimmuNity and Treat Multiple
Principal Investigator: Prof. Clara Ballerini
Funding Agency: Ministry of Health - Targeted Research (Ricerca Finalizzata)
Funding Amount: €67,500
PROJECT TITLE: Leveraging ion channel-based macromolecular complexes for innovative therapies in hard to treat cancers
Principal Investigator: Prof. Annarosa Arcangeli
Funding Agency: AIRC
Funding Amount: €690,000
PROJECT TITLE: NEuroendocrine-metabolic-inflammatory and infection-proneness Profile Testing before, during and after short-term UNderwater and Extraterrestrial missions (NEPTUNE -ISS-SDM)
Principal Investigator: Prof. Amedeo Amedei
Funding Agency: Italian Space Agency
Funding Amount: €50,188
PROJECT TITLE: Towards an AIDS-free Future: synergies for integrated, inclusive, and equitable initiatives in Senegal
Principal Investigator: Prof. Alessandro Bartoloni
Funding Agency: Italian Agency for Development Cooperation
Funding Amount: €85,000
Project Fact Sheet
- Operational Programme: National Operational Programme (PON) “Enterprises and Competitiveness” 2014-2020 ERDF
- Axis / Investment Priority / Action: Axis I – Investment Priority 1b – Action 1.1.3
- Project Code: F/180012/03/X43
- Beneficiary: University of Florence – Department of Experimental and Clinical Medicine
- Total Funding / Support: € 1,199,112.76
Project Title
SVATT: Development and Preclinical Validation of a THERANOSTIC Treatment for Melanoma Cancer Based on the Use of Immune System Cells (T Cells), Enhanced by Loading with Magnetic Nanoparticles to Enable Specific Drug Delivery, Localized Hyperthermia Application, and Advanced MRI Diagnostics.
Purpose
Validation and Product Authorization
Project Rationale
The SVATT project rationale involves validating the use of immune system cells—specifically cytotoxic T CD8+ lymphocytes (CTLs)—selected for their antigenic specificity against melanoma tumors and loaded with NBR21+Curcumin (ferromagnetic nanoparticles conjugated with the drug curcumin, produced by the partner Colorobbia). Utilizing amplification equipment (CELLF, developed by the partner Kayser Italia), this construct can be activated by a magnetic field (via equipment designed by the partner El.En.) to achieve an enhanced tumor-killing effect.
Expected and Achieved Results by UNIFI-DMSC
- Validation and standardization of the engineering method for melanoma-specific cytotoxic lymphocytes using NBR21 and NBR21+Curcumin.
- Validation of CD8+ T lymphocyte amplification and engineering with NBR21 and NBR21+Curcumin within the CELLF device.
- In vitro efficacy proof on tumor cell lines treated with engineered cytotoxic lymphocytes and subjected to hyperthermia.
- In vivo efficacy proof of the treatment on melanoma tumors in animal models.
- Classification request as an Advanced Therapy Medicinal Product (ATMP) for the product developed within the SVATT project, named: CURANBRECLY (Curcumin Activated Nanoparticles engineered C-Lymphocytes).
Last update
19.06.2026